Table 1.

The ranking order of an agonist’s EC₅₀ for PPARγ and neurite length increase in vitro.

Compound	PPARγ EC50	Dose of Compound Tested In Vitro (µM)	Neurite Length Seen with Optimal Dose Percentage Increase to the Control (Mean ± SEM)
GW1929	13 nM [32]	10	51% ± 14.74
Pioglitazone	380 nM [33]	1	40% ± 15.58
Sulindac sulfide	1.87 µM [23]	100	106% ± 24.61
Diclofenac	1 µM [23]	100	73.93% ± 28.65
Ibuprofen	56.8 µM [23]	100	55.2% ± 17.92 [28]
Indomethacin	21 µM [23]	100	19.3% ± 17.35
Naproxen	No action [20]	100	1.8% ± 8.44
GW9662	2 nM [34] Irreversible Antagonist	100	−89% ± 10.41 [28]